Thursday 16 October, 2025
Background: A new paliperidone palmitate 3-month formulation (PP3M) has been developed aiming at retained efficacy compared to the marketed paliperidone 1-month…
Read morePoster: Drug/Disease modeling - CNS
Application of an Item Response Theory model to describe Amyotrophic Lateral Sclerosis Functional Rating Scale data
Thursday 16 October, 2025
Objectives: To develop an Item Response Theory (IRT) model which describes Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) data. The IRT…
Read moreEthnic difference of ADAS-Cog Placebo Response in Patients with Alzheimer’s Disease
Thursday 16 October, 2025
Objectives: Alzheimer’s Disease progressively decreases cognitive function and Alzheimer Disease Assessment Scale (ADAS-Cog) is the standard score used to assess…
Read moreExternal validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data
Thursday 16 October, 2025
Objectives: Antiepileptic drug (AED) monotherapy is preferable to polytherapy, but some patients require more than one AED for successful seizure control….
Read morePopulation modeling of changes in steady–state pharmacokinetics of carbamazepine (CBZ) due to antiepileptic drug-drug interactions from therapeutic drug monitoring (TDM) data
Thursday 16 October, 2025
Objectives: Epilepsy is a chronic disease requiring long term treatment with antiepileptic drugs (AEDs). While monotherapy is considered as the…
Read morePopulation modeling of steady-state pharmacokinetics of carbamazepine (CBZ) and its epoxide metabolite (CBZE) from therapeutic drug monitoring (TDM) data
Thursday 16 October, 2025
Objectives: CBZ is one of the most widely used antiepiletptic drugs for the treatment of partial and tonic-clonic seizures. Its…
Read moreDevelopment of a generic model for brain distributional pharmacokinetics and its translation to clinical data
Thursday 16 October, 2025
Objectives: To develop a generic brain distribution model using rat multilevel brain and plasma data and to translate the model…
Read moreToward a generic PBPK model to predict drug distribution in human brain
Thursday 16 October, 2025
Background: Prediction of drug distribution in human brain is of importance for CNS drug development, but also for non-CNS drug…
Read moreModelling pharmacokinetics and CSF Abeta1-40 reduction in humans after dosing with JNJ-54861911, a novel oral BACE inhibitor
Thursday 16 October, 2025
Objectives: Amyloid reduction via BACE inhibition is a potential therapeutic target in Alzheimer’s Disease [1]. JNJ-54861911 is a potent oral BACE…
Read moreA two-part mixed-effects model for semi-continuous data to describe the effect of transdermal rotigotine on restless legs symptoms in adults
Thursday 16 October, 2025
Objectives: To quantify the dose-exposure-response relationship of rotigotine in adult patients suffering from restless legs syndrome (RLS) and to assess…
Read more